Vericiguat in Heart Failure With Reduced Ejection Fraction With High Natriuretic Peptides: A Case of Too Little, Too Late?

JACC Heart Fail. 2020 Nov;8(11):940-942. doi: 10.1016/j.jchf.2020.09.001. Epub 2020 Oct 7.

Authors

Jonathan W Cunningham¹, Pardeep S Jhund²

Affiliations

¹ Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. Electronic address: jcunningham3@bwh.harvard.edu.
² BHF Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom. Electronic address: https://twitter.com/PSJhund.

PMID: 33039450
DOI: 10.1016/j.jchf.2020.09.001

No abstract available

Keywords: NT-proBNP; clinical trial; vericiguat.

Publication types

Editorial
Comment

MeSH terms

Heart Failure* / drug therapy
Heterocyclic Compounds, 2-Ring*
Humans
Natriuretic Peptide, Brain
Peptide Fragments
Pyrimidines
Stroke Volume

Substances

Heterocyclic Compounds, 2-Ring
Peptide Fragments
Pyrimidines
Natriuretic Peptide, Brain
vericiguat